Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data. Issue 4 (25th January 2018)

• Record Type: Journal Article
• Authors: Lipsitch, Marc; Li, Lucy M.; Patterson, Scott; Trammel, James; Juergens, Christine; Gruber, William C.; Scott, Daniel A.; Dagan, Ron
• Is Part Of: Vaccine. Volume 36:Issue 4(2018)
• Page Start: 473
• Page End: 478
• Publication Date: 2018-01-25
• Subjects: Streptococcus pneumoniae -- Pneumococcal conjugate vaccine -- Antibody response -- Nasopharyngeal colonization; IgG immunoglobulin G -- PCV pneumococcal conjugate vaccine -- ELISA enzyme-linked immunosorbent assay -- PCA principal component analysis -- NP nasopharyngeal -- SNP single nucleotide polymorphism; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.12.015
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Some individuals have stronger immune responses against all serotypes in PCV. Increasing time since vaccination was associated decreasing antibody levels. Older participants tended to have higher antibody levels than younger participants. Abstract: Background: The magnitude of an individual's serotype-specific immunoglobulin G (IgG) response to a pneumococcal conjugate vaccine (PCV) has been associated with the vaccine's protective efficacy against carriage of pneumococci of that serotype, though the relationship with other serotypes needs to be understood. Methods: Using immunogenicity data collected during a trial comparing the 7-valent (PCV7) and 13-valent (PCV13) vaccines, we measured associations between serotype-specific IgG levels, and used multiple regressions to identify demographic predictors of response. Results: Vaccine-induced IgG levels were moderately positively correlated with one another, with pairwise correlation coefficients of 0.40–0.70. Principal component analysis of vaccine-serotype responses yielded one principal component indicating general immune responsiveness, and a second principal component mainly describing responses to serotype 14, which was the least correlated with the other responses. Overall, demographic variables explained only 17.0 and 20.4% of the geometric mean PCV7 and PCV13 responses, respectively. In both groups, older age at the first vaccine dose and shorter time from vaccination to antibody measurement were independently associated with stronger geometric mean responses. Discussion: Improved understanding of the nature and causes of variation in immune response may aid in optimizing vaccination schedules and identifying robust correlates of protection.